IMPL has been the topic of several other reports. Cowen dropped their price objective on Impel Pharmaceuticals to $40.00 in a report on Thursday, November 17th. Wedbush lowered Impel Pharmaceuticals from an outperform rating to a neutral rating and dropped their price objective for the company from $24.00 to $5.00 in a report on Tuesday, November 15th. Finally, Jonestrading initiated coverage on Impel Pharmaceuticals in a research report on Wednesday, August 24th. They issued a buy rating and a $26.00 target price on the stock.
Impel Pharmaceuticals Stock Up 1.9 %
Shares of IMPL opened at $2.73 on Monday. The company has a current ratio of 4.97, a quick ratio of 4.54 and a debt-to-equity ratio of 12.07. Impel Pharmaceuticals has a 12 month low of $2.55 and a 12 month high of $10.75. The stock’s 50 day moving average is $4.44 and its two-hundred day moving average is $6.69. The firm has a market cap of $64.81 million, a P/E ratio of -0.59 and a beta of 0.04.
Hedge Funds Weigh In On Impel Pharmaceuticals
About Impel Pharmaceuticals
Impel Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for patients suffering from central nervous system disease in the United States. Its lead product candidate is Trudhesa, an upper nasal formulation of dihydroergotamine for the acute treatment of migraine.
- Get a free copy of the StockNews.com research report on Impel Pharmaceuticals (IMPL)
- Microsoft Shares: Is it Time to Back Up the Truck?
- Institutional Support for Analog Devices Remains High
- Is the 60/40 Portfolio Mix Still in Vogue?
- Salesforce Cuts Labor, Shows Strong Earnings Despite Challenges
- Three CBD Stocks to Dominate a Budding Industry
Receive News & Ratings for Impel Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Impel Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.